181 related articles for article (PubMed ID: 35244681)
21. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.
Lulla PD; Naik S; Vasileiou S; Tzannou I; Watanabe A; Kuvalekar M; Lulla S; Carrum G; Ramos CA; Kamble R; Hill L; Randhawa J; Gottschalk S; Krance R; Wang T; Wu M; Robertson C; Gee AP; Chung B; Grilley B; Brenner MK; Heslop HE; Vera JF; Leen AM
Blood; 2021 May; 137(19):2585-2597. PubMed ID: 33270816
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
24. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
25. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases.
Frassoni F; Barrett AJ; Grañena A; Ernst P; Garthon G; Kolb HJ; Prentice HG; Vernant JP; Zwaan FE; Gratwohl A
Br J Haematol; 1988 Nov; 70(3):317-20. PubMed ID: 3061443
[TBL] [Abstract][Full Text] [Related]
26. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
27. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
28. [Hematopoietic stem cell transplantation for treatment of acute leukemia].
Harada M
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1387-95. PubMed ID: 10500524
[TBL] [Abstract][Full Text] [Related]
29. Possible clinical benefits of the use of peripheral blood stem cells over bone marrow in the allogeneic transplantation setting for the treatment of childhood leukemia.
Matsubara H; Makimoto A; Takayama J; Higa T; Saito T; Kanda Y; Tanosaki R; Mineishi S; Ohira M; Takaue Y
Jpn J Clin Oncol; 2001 Jan; 31(1):30-4. PubMed ID: 11256838
[TBL] [Abstract][Full Text] [Related]
30. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
[TBL] [Abstract][Full Text] [Related]
31. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
33. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions.
Porter DL; Collins RH; Hardy C; Kernan NA; Drobyski WR; Giralt S; Flowers ME; Casper J; Leahey A; Parker P; Mick R; Bate-Boyle B; King R; Antin JH
Blood; 2000 Feb; 95(4):1214-21. PubMed ID: 10666193
[TBL] [Abstract][Full Text] [Related]
34. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.
Choi SJ; Lee JH; Lee JH; Kim S; Seol M; Lee YS; Lee JS; Kim WK; Chi HS; Lee KH
Leukemia; 2004 Nov; 18(11):1789-97. PubMed ID: 15385924
[TBL] [Abstract][Full Text] [Related]
35. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program.
Miyamoto T; Fukuda T; Nakashima M; Henzan T; Kusakabe S; Kobayashi N; Sugita J; Mori T; Kurokawa M; Mori SI
Biol Blood Marrow Transplant; 2017 Jun; 23(6):938-944. PubMed ID: 28219836
[TBL] [Abstract][Full Text] [Related]
36. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Slavin S; Nagler A; Naparstek E; Kapelushnik Y; Aker M; Cividalli G; Varadi G; Kirschbaum M; Ackerstein A; Samuel S; Amar A; Brautbar C; Ben-Tal O; Eldor A; Or R
Blood; 1998 Feb; 91(3):756-63. PubMed ID: 9446633
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide.
Bostrom B; Weisdorf DJ; Kim T; Kersey JH; Ramsay NK
Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007
[TBL] [Abstract][Full Text] [Related]
38. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia.
Schneidawind C; Hagmaier V; Faul C; Kanz L; Bethge W; Schneidawind D
Ann Hematol; 2018 Dec; 97(12):2491-2500. PubMed ID: 30066039
[TBL] [Abstract][Full Text] [Related]
39. Comparative analysis of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation in children with high-risk or advanced acute leukemia.
Zheng C; Zhu X; Tang B; Yao W; Song K; Tong J; Geng L; Liu H; Sun Z
Ann Hematol; 2015 Mar; 94(3):473-80. PubMed ID: 25217231
[TBL] [Abstract][Full Text] [Related]
40. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
